Method for retarding or precluding alzheimer's dementia
AssigneeSyn X Pharma, Inc.
InventorsGeorge Jackowski, Shirley Furesz
Life of this patent
Estimating the term…
Abstract
A method for treating a condition related to the development of Alzheimer's disease(AD) is disclosed. The method involves the removal of circulating autoantibodies of a biochemical marker or markers, specifically human glial fibrillary acidic protein (GFAP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), from the sera of a patient in an amount effective to reduce or eliminate phagocytosis of astrocytic cells. The invention further includes a process of immune system modulation effective for autoantibody removal.
Claims2
A process for retarding or eliminating the process of phagocytosis in astrocytic cells comprising:
- determining the presence in circulating body fluid of autoantibodies against at least one biochemical marker selected from the group consisting of glial fibrillary acidic protein (GFAP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH);
- and
- removing from said circulating body fluid an amount of said autoantibodies effective to retard or eliminate the onset of phagocytosis of astrocytic cells.
Dependencies are inferred from the claim text.